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Introduction 
 
Premenstrual Dysphoric Disorder (PMDD) is characterized by extreme mood 
symptoms that emerge cyclically in the late luteal phase of the menstrual cycle and 
subside during menses. About 3-8% of women meet the full DSM-5 criteria1,2 for PMDD, 
which requires the presentation of five symptoms (at least one being an emotional 
symptom) following the cyclical pattern per cycle, while another 10-11% of women can 
be characterized as having a less severe menstrually-related mood disorder (MRMD), 
which requires just one emotional symptom to follow the cyclical pattern per cycle2. 
Women with signs of MRMD have less severe emotional symptoms than those with 
PMDD. However, both PMDD and MRMD can cause impairment and distress severe 
enough to warrant treatment.  
Diagnosis of PMDD or MRMD must follow strict criteria established by the DSM-5 
over a period of at least two months of prospective daily symptom ratings. Since 
retrospective reports of these symptoms is highly subjective and inaccurate, valid 
diagnosis requires prospectively evaluating daily symptoms against the diagnostic 
criteria3,4. Typically, symptoms are evaluated through visual inspection of daily ratings 
across multiple cycles; however, differences in interpretation of the diagnostic criteria 
during these visual inspections may lead to inconsistencies. Furthermore, the complex 
diagnostic criteria outlined in the DSM-5 means there is a high risk of diagnostic error 
due to differing practices and errors in clinical judgment. These concerns suggest the 
need for a more reliable method for making valid prospective diagnoses. In response to 
this need, Eisenlohr-Moul et al. (under review) have developed the Carolina 
Premenstrual Assessment Scoring System (or C-PASS), a computerized standardized 
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diagnostic system aimed at creating shared meaning for PMDD and MRMD across 
laboratories. Although the C-PASS, described in more detail below, represents an 
essential step forward in our standardization of these diagnoses, additional work is 
needed to verify that the cut points selected for making the diagnosis are adequate for 
identifying the subgroup of women that need treatment. The purpose of the present 
paper is to use descriptive statistics and ROC analyses to examine how changes to 
these diagnostic cutoffs influence the frequency and appropriateness of diagnoses.  
 
Defining the DSM-5 Diagnostic Dimensions and Mapping Them onto a Widely-
Used Assessment Tool 
The DSM-5 outlines four key diagnostic dimensions for characterizing PMDD: 
content, cyclicity, clinical significance, and chronicity. The content dimension requires 
that five symptoms are met and at least one of those symptoms must be a core 
symptom such as depression, anxiety, mood lability, or anger/irritability. A MRMD 
diagnosis only requires that one core symptom is present.  The cyclicity dimension 
refers to the relative symptom elevation and the absolute symptom clearance. Relative 
premenstrual symptom elevation is met if the symptom shows at least a 30% decrease 
in severity from the premenstrual week to the postmenstrual week. Absolute symptom 
clearance is met if a symptom does not exceed a Likert score of three out of a 
maximum of six on any day during the postmenstrual week. The clinical significance 
dimension refers to the absolute severity of the symptoms and their duration. This 
dimension requires that the symptoms must be of sufficient absolute severity and 
duration in the pre-menstrual week to be classified as clinically significant. The 
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chronicity dimension requires that the dimensions of content, cyclicity, and clinical 
significance be present for a majority of the cycles.  
The DSM-5 does not provide numerical equivalences for the diagnostic 
dimensions, which is part of the reason for subjectivity and variability in PMDD 
diagnostic practices. However, the Daily Record of Severity Problems form (DRSP) 
allows for the numerical assessment of the criterion described for the four diagnostic 
dimensions (Table 9). The DSM-5 content for PMDD and MRMD is completely 
contained within the DRSP’s twenty-one symptoms. The DRSP asks the rater to 
indicate the daily severity of these twenty-one symptoms on a 6-point Likert scale. A 
score of one indicates the symptom was not at all present and a score of six indicates 
an extreme presence of the symptom. 
The C-PASS was created to standardize the complicated PMDD diagnosis. 
While the diagnosis in the C-PASS was created according to the DSM-5, certain 
numeric threshold decisions were made to ensure that the C-PASS outcome was 
reasonable and warranted diagnosis and treatment. Although the C-PASS represents 
an important first step in standardizing the diagnoses of PMDD and MRMD, the present 
paper examines whether the cutoff values on the DRSP that were selected for the C-
PASS criteria are appropriate in terms of selecting a group of women that requires 
treatment. In this paper, we re-examine the sample of women seeking a diagnosis of 
MRMD, using descriptive statistics and logistic/ROC analyses to understand whether 
the current cut points are appropriate for identifying women in need of treatment.  
 Several variations in calculation methods and thresholds for diagnosis were 
considered. First, we compare diagnostic frequencies using follicular maximum ratings 
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or follicular mean ratings to evaluate absolute clearance (see above). Second, we 
assessed descriptive changes when altering the thresholds for the number of symptoms 
needed per cycle, relative symptom elevation threshold, severity and clearance 
threshold, and the threshold for duration of severe symptoms. In order to determine the 
number of symptoms per cycle and the number of severe days (duration) per cycle at 
which cyclicity of life impairment is present, we also conducted an ROC analyses for 
these predictors (using the efficiency criterion to select an optimal cutpoint). These 
analyses will be described and discussed in terms of their relevance for understanding 
the disorder and improving the C-PASS diagnostic system. 
 
Methods 
Description of the C-PASS Diagnostic Method 
The diagnostic process begins by characterizing each DRSP item in each cycle 
(where a cycle is defined as a set of contiguous postmenstrual and premenstrual weeks 
from two consecutive menstrual cycles) using the four diagnostic dimensions as 
described in Table 10 (relative symptom elevation: percent symptom elevation during 
premenstrual phase relative to postmenstrual phase >=30%; absolute clearance: 
postmenstrual week maximum <=3; absolute severity: premenstrual week maximum 
>=4; and duration: severe premenstrual week days >=2). Because DSM-5 diagnosis of 
PMDD is clearly defined as a marked on-off pattern occurring in the perimenstrual 
timeframe, the C-PASS utilizes the premenstrual week (defined as days -7 to -1, where 
-1 is the day prior to menstrual onset) and the postmenstrual week (defined as the 7 
days following average menstrual offset: days 4 to 10, where day 1 represents 
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menstrual onset). That is, the rationale for comparing the premenstrual week of one 
menstrual cycle to the contiguous follicular postmenstrual week of the next cycle is to 
establish the “switch off” of symptoms, as it is critical to demonstrate that the cyclical 
symptoms do not persist into the follicular phase. Further, the C-PASS requires that at 
least 3 out of 7 ratings be present in each of the two weeks from each cycle, and 
requires at least two cycles (i.e., contiguous pairs of premenstrual-postmenstrual 
phases).  
Next, cycle-level diagnosis of PMDD is made by counting DSM-5 symptoms 
meeting criteria on all four dimensions (see Table 9; Total Symptoms: 1-4 for MRMD 
and >=5 for PMDD) and whether a core symptom meets criteria (number of core 
symptoms >=1). Next, the C-PASS makes the diagnosis of MRMD or PMDD at the 
person level by counting the number of cycles meeting diagnostic criteria for either 
MRMD or PMDD (cycles meeting criteria >=2). Finally, the C-PASS concatenates a 
visual representation of relevant information for each DRSP item across as many cycles 
as provided, along with a determination of cycle-level diagnosis for that symptom in 
each cycle. The system also outputs a dataset with individual difference variables for 
each diagnostic dimension. In the present study, the research diagnosis of MRMD5 (i.e., 
1-4 symptoms met for at least 2 cycles, of which one must be a core emotional 
symptom) was calculated in addition to PMDD.  
 
Participants, Procedure, and Materials 
The study sample consisted of 267 naturally cycling women between ages 18 
and 47 (M = 32.70, SD = 8.21) with regular menstrual cycles (21–35 days). Women with 
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pregnancy, chronic medical disorders, history of certain psychiatric symptoms (mania, 
substance dependence, psychosis), or certain prescription medications (any 
antidepressant, benzodiazepines, neuroleptics, or any hormonal preparation) were 
excluded. All procedures were approved by the IRB, and all participants provided 
informed consent. These participants were not paid.  
Subjects were recruited at the University of North Carolina using posters, flyers, 
and e-mail over a six-year period (2009-2015). All recruitment materials specified that 
the purpose of this study was to assess menstrual cycle-related psychological and 
somatic problems. An initial telephone screening was conducted to assess inclusion 
and exclusion criteria. Baseline visits were also scheduled for eligible participants during 
these interviews. During the 45-minute baseline visits, subjects’ medical and medication 
histories were recorded, and the SCID-1 was administered to assess for Axis I 
psychiatric disorders. 
Prospective assessment of menstrual cycle-related symptoms was completed 
using 2-4 months of daily participant diaries. Participants completed daily ratings using 
the DRSP (see above for description) and reported menstrual flow. Participants were 
also able to report external events, circumstances, or stressors they believe may be 
associated with their daily well-being. Days where participants reported the occurrence 
of a substantial external stressor were treated as missing data. These forms were 
mailed in weekly. In the final sample, 200 women had provided sufficient prospective 
data and 67 women had been eliminated based upon an insufficient amount of data. 
 
Analytic Plan  
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Descriptive tables were produced to compare the use of two different statistics 
for the evaluation of absolute premenstrual severity and absolute postmenstrual 
symptom clearance: follicular maximum rating versus  follicular mean rating. Four 
different thresholds were then varied for relative symptom elevation, absolute severity 
and clearance, duration, number of severe symptoms. After conducting multilevel 
(cycles nested within women) logistic regressions, receiver operating curves were 
created to determine the optimal cutpoint for both 1) number of symptoms per cycle and 
2) number of severe days per cycle on each DRSP item. The dichotomous outcome 
was whether or not the cycle met C-PASS criteria on any impairment item. Impairment 
is met when a symptom meets C-PASS criteria for any of the following three DRSP 
items: interference with work, interference with hobbies or social life, and interference 
with relationships. The symptom must meet C-PASS criteria for at least one of C-PASS 
criteria for cyclical impairment to be met. SAS 9.5 ROCPLOT macro was used to 
determine the optimal cut points using the efficiency method. The efficiency calculation 
utilizes prevalence to weight the specificity and sensitivity and is calculated using the 
following formula:  
p×Sensitivity + (1-p)×Specificity. 6 
While other optimal cut point calculations in SAS 9.3, such as the Youden index, 
assume a 50% base rate within the sample, the efficiency method takes the true base 
rate of the sample into account. An assumption of a 50% base rate was not deemed 
appropriate given the base rates described earlier. Using the base rates within the 
sample will provide us with estimates most accurate for women seeking PMDD and 
MRMD diagnoses. Furthermore, we opted for a cut point calculation method that does 
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not account for the cost of incorrect diagnosis. Currently, there is little evidence 
available on which to conduct a cost-benefit analysis regarding the clinical detriments of 
false positives vs. false negatives in PMDD; thus the decision was made to ignore the 




 267 women contributed 563 cycles to the analysis. 170 cycles (30.20%) were 
characterized by significant cyclical impairment, 285 cycles (50.62%) received the C-
PASS MRMD diagnosis, and 149 cycles (26.46%) received the more stringent PMDD 
diagnosis. All analyses were carried out in SAS 9.5. Each cycle also received a 
dichotomous decision regarding the presence of significant cyclical interference 
following the C-PASS method for diagnosing symptoms described above. 
Relative premenstrual symptom elevation may be calculated using either the phase 
average severity for each symptom or the phase maximum severity for each symptom. 
Diagnosis frequencies within the sample were compared when each method of 
calculation was used (Table 1). Upon inspection of the descriptive statistics, it appears 
that using follicular mean in the calculation is a less stringent method of diagnosis. 
Further, within each method of absolute symptom clearance calculation (follicular 
maximum and follicular mean), the following thresholds were varied and descriptives 
presented: percent threshold for relative premenstrual symptom elevation, the absolute 
severity and clearance threshold, the symptom duration thresholds, and the number of 
symptoms required to meet criteria were varied.  
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Table 1. Comparing Changes in C-PASS Diagnosis when varying premenstrual 










Relative Symptom Elevation Thresholds. Relative symptom elevation 
calculation using mean severity for the follicular phase resulted in 22% of the 
participants diagnosed with PMDD when a 30% threshold for relative symptom 
elevation was specified (Table 2). This number of patients diagnosed decreased 
dramatically when the threshold for relative symptom elevation was increased to 50% 
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Table 2. Impact of Varying % Threshold for Relative Premenstrual Symptom Elevation 
 
Absolute Symptom Severity and Clearance Thresholds. Absolute severity 
thresholds greater than or equal to 3 and absolute clearance thresholds less than or 
equal to three resulted in a 28% diagnosis of PMDD (Table 3). Although this percentage 
on PMDD diagnosis decreased (22%) when the threshold was increased to 4, the 
percentage of MRMD diagnoses remained the same (25%). A threshold of 5 further 
decreased the percentage of MRMD diagnosis and PMDD diagnosis (Table 3). Trends 
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Table 3. Determination of Absolute Severity and Clearance Thresholds  
 
 
Duration Thresholds. The duration of symptoms was varied from two to five 
days and frequencies of PMDD and MRMD diagnosis generally decreased as the 
threshold of days increased (Table 4). Trends were similar when follicular maximum 
was used. 
 
Table 4. Duration of Symptoms 
 C-PASS Diagnosis with Absolute Severity and Clearance Varied 
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Symptom Thresholds. The number of severe symptoms needed for each cycle 
to meet C-PASS criteria was also varied. Table 5 shows the frequency results as 
number of symptom threshold was varied from two to five. The current threshold is set 
at five symptoms. As one would expect, as the stringency of the threshold is increased, 
the frequency of diagnosis decreases.  
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Using Multilevel Logistic Regression and ROC Curves to Determine the Optimal 
Number of 1) DSM-5 Symptoms per Cycle and 2) Severe Days per Cycle to Predict 
the Presence of Moderate Cyclical Impairment 
Next logistic multilevel models in which cycles were nested within women were 
used to predict cycle-level presence of significant cyclical interference from number of 
DSM-5 symptoms meeting C-PASS criteria in that cycle; number of symptoms meeting 
criteria was indeed predictive of whether or not the cycle was characterized by 
impairment (Estimate: .59, SE = .049, t(295) = 11.99, p < .0001). Random effects for 
number of symptoms were not significant, suggesting that the size and direction of the 
effect of number of symptoms per cycle on impairment in a given cycle was similar 
across women. Information regarding predicted values was saved from this model and 
averaged across each number of symptoms. PROC LOGISTIC was utilized to calculate 
the area under the ROC curve (AUC = .9017, 95% CI: .87 to .92). Finally, the SAS 
ROCPLOT macro6 was utilized to graph the ROC curve (see Figure 1) and the 
efficiency criterion was utilized to select the optimal number of symptoms per cycle for 
predicting the presence of significant cyclical interference, which was 4 symptoms.   






















Figure 1. ROC Curve Predicting Presence of Impairment in this Cycle from Number of 
Symptoms Meeting DSM-5 Criteria this Cycle 
 
Table 6. ROC Curve Analysis Results for Number of Symptoms Meeting DSM-5 Criteria 











0.9017 0.8742 0.9293 -0.41359 
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Therefore, despite the fact that the DSM-5 does not require the presence of interference 
to make the diagnosis of PMDD (this is a shift from DSM-IV), this ROC analysis 
suggests that the number of DSM-5 symptoms per cycle at which significant cyclical 
impairment can be optimally predicted is 4, which is LOWER than the number of  
symptoms per cycle (5) needed to make the official diagnosis of DSM-PMDD. In similar 
ROC analyses conducted for the number of severe days on each DRSP item needed to 
predict moderate cyclical impairment, the number of severe days needed to cause 
impairment by each symptom ranged from two days to seven days. In general, it 
appears that high arousal symptoms such as anxiety and irritability require a greater 
amount of severe days within a cycle to cause impairment. Low arousal psychological 
symptoms require a lower number of severe days to cause impairment. Most DRSP 
items required either three days or five days to cause impairment. Physical symptoms 
generally needed five to seven days to cause impairment, indicating that they are may 
not be the key symptoms of PMDD in terms of driving impairment. A summary of these 
ROC analyses can be found in Tables 7 and 8. Table 8 excludes DRSP 2, headaches, 
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Table 7.  Summary of ROC curve analyses results for number of severe days predicting 























DRSP 1 0.7425 0.6974 0.7877 0.22176 
4 
 
DRSP 2 0.6839 0.6388 0.7290 -0.41264 
2 
 
DRSP 3 0.6796 0.6357 0.7234 -0.063947 
3 
 
DRSP 4 0.7649 0.7217 0.8080 0.23155 
5 
 
DRSP 5 0.7868 0.7457 0.8279 0.40310 
5 
 
DRSP 6 0.7870 0.7463 0.8278 -0.25939 
3 
 
DRSP 7 0.8345 0.7995 0.8694 0.53480 
5 
 
DRSP 8 0.8185 0.7803 0.8567 -0.096879 3 
DRSP 9 0.7919 0.7510 0.8328 -0.097786 3 
DRSP 10 0.7741 0.7318 0.8164 -0.17985 3 
DRSP 11 0.7872 0.7465 0.8279 0.33197 5 
DRSP 12 0.7391 0.6943 0.7839 -0.29633 3 
DRSP 13 0.7181 0.6722 0.7640 0.070238 4 
DRSP 14 0.7565 0.7137 0.7994 0.029269 4 
DRSP 15 0.6927 0.6445 0.7409 0.52389 5 
DRSP 16 0.7620 0.7185 0.8054 -0.057696 3 
DRSP 17 0.7650 0.7225 0.8075 0.20529 3 
DRSP 18 0.6735 0.6268 0.7202 0.10991 5 
DRSP 19 0.7314 0.6868 0.7760 0.87214 7 
DRSP 21 0.6572 0.6098 0.7045 0.53208 5 
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Table 8. The number of severe days required on each DRSP item to optimally predict 
the presence of at least moderate impairment cyclicity.  
 
Discussion 
Variations in approaches to making the diagnosis of premenstrual dysphoric 
disorder compromise the validity of PMDD and undermine our ability to identify and treat 
women suffering from the disorder. The Carolina Premenstrual Assessment Scoring 
System (C-PASS) seeks to streamline the diagnosis process and create diagnostic 
uniformity within the field. Although many of the diagnostic decisions made within the C-
PASS have been recommended by the DSM-5, certain decisions made within the C-
PASS required further inspection to understand how changing them might alter the 
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Calibration of Prospective Diagnosis in PMDD   18
prevalence of diagnosis. The sample used consisted of women seeking evaluation for 
PMDD and willing to participate in a research study. 
Descriptive statistics were calculated for a variety of permutations of thresholds 
and methods to provide information about how changing these thresholds and methods 
might influence diagnostic prevalence. ROC curves were examined regarding the 
number of symptoms per cycle needed to predict moderate impairment, which is an 
outcome used in order to identify a subgroup of women who require treatment. ROC 
curves were also created for each DRSP symptom to determine the optimal number of 
severe days required to see at least moderate impairment.  
 
Findings and Implications 
The ROC in figure 1 shows that four symptoms is the optimal number of 
symptoms that should be required to diagnose PMDD. This finding is consistent with 
findings from the Harvard Study of Moods and Cycles, which found that a community-
based sample needed six symptoms while a clinical sample only required two 
symptoms7. The average value of these two very different samples once again confirms 
that four symptoms is likely the ideal number for diagnosing PMDD. This threshold of 
four symptoms differs from the five symptom requirement by the DSM-5. Our findings 
suggest that the current five symptom threshold in the DSM-5 may be too stringent and 
cause missed diagnoses.  
In general the ROC curves (Tables 6 and 7) showed that 3 days and 5 days of 
severity were sufficient to cause impairment by most symptoms. Table 7 shows the vast 
differences in each DRSP item and the optimal number of days to cause cyclical 
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impairment by that item. Therefore, the current DSM-5 requirement of 2 severe days per 
symptom might potentially be too lax.  
Variations of threshold produced the expected effect of diagnosing more patients 
as the thresholds were made more stringent. It does not appear that utilizing the 
follicular maximum versus the follicular mean creates a large, substantial difference in 
the number of PMDD diagnoses made. The C-PASS utilizes follicular maximum, and 
this decision appears to be justified at the present time.   
 
Limitations of this study 
While this study examined impairment caused by PMDD symptoms, the DRSP 
interference items were the only measures used to establish impairment. Further work 
could be improved by including alternative validity measures at the daily level for both 
distress and impairment. Furthermore, this study has issues of generalizability. The 
women included in this study were actively seeking aid for PMDD and were willing to 
participate in research studies. This may not be representative of the entire community 
of women suffering from PMDD, and it is likely that many “silent sufferers” of the 
disease may not have been represented. A community-based cohort would provide a 
more representative group. On the other hand, this sample does represent the current 
normative sample used by most laboratories when studying PMDD—women who 
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Conclusions 
The Carolina Premenstrual Assessment Scoring System seeks to systematically 
diagnose and standardize premenstrual dysphoric disorder. The descriptive 
examination of diagnostic thresholds presented here demonstrates that, while the 
majority of the decision rules incorporated in the C-PASS are defensible, further work is 
needed to determine whether some of the decision rules should be altered. In particular, 
the current threshold of five symptoms to reach PMDD diagnosis may be too stringent, 
given that just four symptoms were necessary in the present study to predict impairment 
cyclicity, and the current threshold of two severe premenstrual days of symptoms may 
be too lax, given that four severe days were necessary here in order to predict 
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CORE SYMPTOMS / CRITERION B 
DRSP 5. Had mood swings (e.g. suddenly felt sad or tearful) 
1. Marked affective lability (e.g., mood swings; feeling 
suddenly sad or tearful, or increased sensitivity to rejection) 
DRSP 6. Was more sensitive to rejection or my feelings were 
easily hurt 
DRSP 7. Felt angry, irritable 
2. Marked irritability or anger or increased interpersonal 
conflicts 
DRSP 8. Had conflicts or problems with people 
DRSP 1. Felt depressed, sad, “down” or blue 
3. Marked depressed mood, feelings of hopelessness, or self-
deprecating thoughts 
DRSP 2. Felt hopeless 
DRSP 3. Felt worthless or guilty 
DRSP 4. Felt anxious, “keyed up”, or “on edge” 4. Marked anxiety, tension, and/or feelings of being keyed up 
or on edge 
ADDITIONAL SYMPTOMS / CRITERION C 
DRSP 9. Had less interest in usual activities (e.g. work, school, 
friends, hobbies) 
1. Decreased interest in usual activities (e.g. work, school, 
friends, hobbies) 
DRSP 10. Had difficulty concentrating 2. Subjective difficulty in concentration 
DRSP 11. Felt lethargic tired, fatigued, or had a lack of energy 3. Lethargy, easy fatigability, or marked lack of energy 
DRSP 12. Had increased appetite or overate 
4. Marked change in appetite; overeating; or specific food 
cravings 
DRSP 13. Had specific food cravings 
DRSP 14. Slept more, took naps, found it hard to get up 
5. Hypersomnia or Insomnia 
DRSP 15. Had trouble getting to sleep, staying asleep 
DRSP 16. Felt overwhelmed, that I couldn’t cope 
6. A sense of being overwhelmed or out of control 
DRSP 17. Felt out of control 
DRSP 18. Had breast tenderness 
7. Physical symptoms such as breast tenderness or swelling, 
joint or muscle pain, sensation of “bloating”, or weight gain 
DRSP 19. Had breast swelling, felt bloated, or had weight gain 
DRSP 21. Had Joint or muscle pain  
DRSP 20. Had headache  
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Table 10. Diagnostic Dimensions of DSM-5 Premenstrual Dysphoric Disorder 




felt depressed/sad/down/blue, felt hopeless, felt worthless/guilty, felt 
anxious/keyed up/on edge, had mood swings, was more sensitive to 
rejection/feelings were easily hurt, felt angry/irritable, had conflicts/problems 
with other people 
Secondary symptoms: 
less interest in usual activities, difficulty concentrating, 
lethargic/fatigue/tired/lack of energy, increased appetite/overate, specific food 
cravings, slept more/took naps/hard to get up, trouble getting to sleep/staying 
asleep, felt overwhelmed/couldn’t cope, felt out of control, breast tenderness, 
breast swelling/felt bloated/weight gain, headache, joint or muscle pain 
Impairment symptoms:  
“Less productivity at work, school, home or in daily routine” 
“Interference with hobbies or social activities (avoid, do less)” 
“Interference with relationships” 
Criterion B:  
affective lability, irritability/anger/increased interpersonal 
conflicts, depressed mood/feelings of hopelessness/self-
deprecating thoughts, anxiety/tension/feelings of being keyed 
up/on edge 
Criterion C: 
decreased interest, difficulty in concentration, lethargy/easy 
fatigability/lack of energy, change in appetite, 
hypersomnia/insomnia, overwhelmed/out of control, physical 




≥ 1 core symptom 
 
PMDD 
≥ 1 core symptom 
≥ 5 total symptoms  
Criterion A:  





30% (relative to range of scale used) decrease from pre-menstrual week (days 
-7  -1) to postmenstrual week (days 4  10) where -1 is the day prior to 
menstrual onse and 1 is menstrual onset 
Criterion A:  
“…present in the week before menses…improve within a few 




Symptoms must not exceed  a value of 3 on any day during days 4  10 
Criterion A:  
“minimal or absent in the week postmenses” 
 






4 or more (on a Likert-scale from 1 to 6) 
Criterion D:  
“symptoms are associated with clinically significant distress 
OR interference with work, school, usual social activities, or 
relationships with others” 
Premenstrual 
Duration 
At least 2 days (doesn’t have to be consecutive) 
Criterion D:  
“in the final week before the onset of menses” 
Not Simply Cyclicity of 
Other Disorder 
Rule out dysmenorrhea using prospective ratings. 
Rule out mood and anxiety disorder with SCID-1.  
Rule out Borderline Personality Disorder with SCID-2. 
Criterion E:  
“not merely an exacerbation of the symptoms of another 
disorder.”  
“Key differential diagnoses: dysmenorrhea, bipolar disorder, 
MDD, dysthymia, and BPD.” 
Chronicity 
≥ 2 symptomatic months 
 
Criterion A and F:  
“In the majority of menstrual cycles…” 
“…should be confirmed by prospective daily ratings during at 
least two symptomatic cycles.” 
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